Genmab AS (NASDAQ:GMAB) is a biotech firm focusing on creating transformative antibody therapies for cancer treatment. The company is traded on the NASDAQ under the ticker symbol GMAB and on the Copenhagen Stock Exchange as (CSE:GEN). Genmab's operations span the discovery and development of novel monoclonal antibodies, a type of protein designed to interact with specific targets in the body. Its projects include proprietary product candidates and partnerships with other pharmaceutical companies to leverage its technology platforms, DuoBody, HexaBody, DuoHexaBody, and HexElect. Genmab's objectives center on using its innovative antibody technology to address unmet medical needs in oncology, aiming to improve the lives of cancer patients worldwide. The company's commitment to innovation and patient care drives its ongoing research, development, and commercialization efforts in the field of cancer therapeutics.